Endu
(Recombinant Human Endostatin Injection)
Recombinant human endostatin is a genetically engineered protein that interferes with the growth of blood vessels to a tumor, thereby starving and preventing the growth of tumor cells. Endu is a modified version of endostatin. Endu has been engineered to contain an additional nine-amino acid sequence to enhance protein purification, solubility and stability and has been shown to improve the function of endostatin. In June 2007, the Company acquired an additional 10% equity interest in Yantai Medgenn. The Company is conducting Phase IV clinical trials for Endu in approximately 150 hospitals in China.
Read more about this topic: Simcere Pharmaceutical